

CERTIFICATE

Survey of 19 May 2023

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Preeclampsia Marker (625):

Validity 12 months:

PLGF (placental growth factor)

sFLT-1 (soluble fms-like tyrosine kinase-1)


(R) analysis is subject to the RiliBÄK

Participant:

42935

MUDr.,PhD. Tomas Salek
Krajska nemocnice T.Bata, a.s.
Department of Clinical Biochemistry &
Pharmacology
Havlickovo nabrezi 600
76275 Zlin

Düsseldorf, 13 June 2023



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Peter B. Lupp
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 19 May 2023

You have participated in the External Quality Assessment with the following analysis

Preeclampsia Marker (625):

PLGF (placental growth factor)

sFLT-1 (soluble fms-like tyrosine kinase-1)

(R) analysis is subject to the RiliBÄK

Participant:

42935

MUDr.,PhD. Tomas Salek
Krajska nemocnice T.Bata, a.s.
Department of Clinical Biochemistry &
Pharmacology
Havlickovo nabrezi 600
76275 Zlin

Düsseldorf, 13 June 2023



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Peter B. Lupp
(Adviser)